Patents Assigned to Cytovia, Inc.
  • Caspase inhibitors and the use thereof
    Patent number: 6716818
    Abstract: The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R1-R3, X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: November 14, 2001
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Eckard Weber, Yan Wang, Gordon B Mills, Douglas R Green
  • Substituted N?-(Arylcarbonyl)-benzhydrazides, N?(Arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Patent number: 6716859
    Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: wherein Ar1, Ar2, and R1-R2 are defined herein. The present invention also relates to the discovery that compounds having Formulae I and II are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John Drewe, Han-Zhong Zhang
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
    Patent number: 6716851
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: wherein A, Ar1, Ar2, R1 and R3 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. The compounds of this invention may be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: December 12, 2001
    Date of Patent: April 6, 2004
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Bao Nguyen, Azra Pervin
  • Novel fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
    Publication number: 20030208037
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Application
    Filed: May 6, 2002
    Publication date: November 6, 2003
    Applicant: Cytovia, Inc.
    Inventors: Han-Zhong Zhang, Sui Xiong Cai, John A. Drewe, Wu Yang
  • Dipeptide apoptosis inhibitors and the use thereof
    Publication number: 20030181391
    Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: 1
    Type: Application
    Filed: May 5, 2003
    Publication date: September 25, 2003
    Applicant: Cytovia, Inc.
    Inventors: John F.W. Keana, Sui Xiong Cai, John Guastella, Wu Yang, John A. Drewe, Eckard Weber
  • Substituted 2-aminobenzamide caspase inhibitors and the use thereof
    Publication number: 20030181388
    Abstract: The present invention is directed to novel 2-aminobenzamide thereof, represented by the general Formula I: 1
    Type: Application
    Filed: May 9, 2003
    Publication date: September 25, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Yan Wang, Eckard Weber, Gordon B. Mills, Douglas R. Green
  • Substituted 2-aminobenzamide caspase inhibitors and the use thereof
    Patent number: 6620782
    Abstract: The present invention is directed to novel 2-aminobenzamide thereof, represented by the general Formula I: where R1-R3, X, and A—D are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: March 16, 2000
    Date of Patent: September 16, 2003
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Yan Wang
  • Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
    Patent number: 6613762
    Abstract: The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: wherein R1-R5 are defined in the specification.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: September 2, 2003
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Shailaja Kasibhatla, Federico C. Gaeta
  • Dipeptide apoptosis inhibitors and the thereof
    Patent number: 6596693
    Abstract: The present invention is directed to novel dipeptides thereof, represented by the general Formula I: where R1-R3 and AA are defined herein. The present invention relates to the discovery that compounds having Formula I are potent inhibitors of apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: August 31, 2000
    Date of Patent: July 22, 2003
    Assignee: Cytovia, Inc.
    Inventors: John F. W. Keana, Sui Xiong Cai, John Guastella, Wu Yang, John A. Drewe, Eckard Weber
  • Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030114485
    Abstract: The present invention is directed to substituted coumarins and quinolines and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: May 16, 2002
    Publication date: June 19, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Hong Zhang, William E. Kemnitzer, Songchun Jiang, John Drewe, Richard Storer
  • Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030105140
    Abstract: The present invention is directed to substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: November 19, 2002
    Publication date: June 5, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, Han-Zhong Zhang
  • Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
    Patent number: 6566338
    Abstract: The use of caspase inhibitors for treating, ameliorating, and preventing non-cancer cell death during chemotherapy and radiation therapy and for treating and ameliorating the side effects of chemotherapy and radiation therapy of cancer is disclosed.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: May 20, 2003
    Assignee: Cytovia, Inc.
    Inventors: Eckard Weber, Gordon B. Mills, Douglas R. Green
  • Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
    Publication number: 20030078292
    Abstract: The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: 1
    Type: Application
    Filed: February 6, 2002
    Publication date: April 24, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Shailaja Kasibhatla, Federico C. Gaeta
  • Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
    Publication number: 20030069239
    Abstract: The present invention is directed to substituted 2-aryl-4-arylaminopyrimidine and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: December 12, 2001
    Publication date: April 10, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, John A. Drewe, P. Sanjeeva Reddy, Bao Nguyen, Azra Pervin
  • Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030065018
    Abstract: The present invention is directed to substituted 4H-chromenes and analogs thereof, represented by the general Formula I: 1
    Type: Application
    Filed: May 16, 2002
    Publication date: April 3, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Hong Zhang, Songchun Jiang, Richard Storer
  • Methods of identifying potentially therapeutically selective and effective anti-cancer agents that are inducers of apoptosis
    Publication number: 20030027229
    Abstract: Disclosed are methods for identifying potential therapeutically effective anti-cancer agents. In particular, the invention relates to the use of biochemical and cell based screening assays to identify compounds that directly or indirectly activate the apoptosis cascade and further a method for identifying those apoptosis inducers that are selective and effective apoptosis agents for use in treating cancer and other therapeutic indications characterized by a lack of appropriate apoptosis. Also disclosed is a method of identifying selective caspase inducers using a cell-line specific primary screen.
    Type: Application
    Filed: January 16, 2002
    Publication date: February 6, 2003
    Applicant: Cytovia, Inc.
    Inventors: Shailaja Kasibhatla, P. Sanjeeva Reddy, John A. Drewe
  • Substituted N'-(arylcarbonyl)-benzhydrazides, N'-(arylcarbonyl)-benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030013743
    Abstract: The present invention is directed to substituted N′-(arylcarbonyl)-benzhydrazides, N′-(arylcarbonyl)-benzylidene-hydrazides and analogs thereof, represented by the Formulae I and II: 1
    Type: Application
    Filed: May 10, 2002
    Publication date: January 16, 2003
    Applicant: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Shailaja Kasibhatla, John Drewe, P. Sanjeeva Reddy, Han-Zhong Zhang
  • Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
    Patent number: 6495522
    Abstract: The present invention is directed to novel substituted &agr;-hydroxy acid thereof, represented by the general Formula I: where R1-R5, X and Z are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: December 17, 2002
    Assignee: Cytovia, Inc.
    Inventors: Yan Wang, Sui Xiong Cai, Eckard Weber, Gordon B. Mills, Douglas R. Green, Lufeng Guan
  • Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
    Publication number: 20020150885
    Abstract: The present invention relates to novel fluorescent dyes, novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of caspases and other enzymes involved in apoptosis in whole cells, cell lines and tissue samples derived from any living organism or organ. The reporter molecules and assay processes can be used in drug screening procedures to identify compounds which act as inhibitors or inducers of the caspase cascade in whole cells or tissues. The reagents and assays described herein are also useful for determining the chemosensitivity of human cancer cells to treatment with chemotherapeutic drugs. The present invention also relates to novel fluorogenic and fluorescent reporter molecules and new enzyme assay processes that can be used to detect the activity of type 2 methionine aminopeptidase, dipeptidyl peptidase IV, calpain, aminopeptidase, HIV protease, adenovirus protease, HSV-1 protease, HCMV protease and HCV protease.
    Type: Application
    Filed: September 7, 2001
    Publication date: October 17, 2002
    Applicant: Cytovia, Inc.
    Inventors: Eckard Weber, Sui Xiong Cai, John F.W. Keana, John A. Drewe, Han-Zhong Zhang
  • Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis
    Patent number: 6462041
    Abstract: The present invention is directed to gambogic acid, analogs and derivatives thereof, represented by the general Formulae I-III: wherein R1-R5 are defined herein. The present invention also relates to the discovery that compounds having Formula I-III are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled cell growth and spread of abnormal cells occurs.
    Type: Grant
    Filed: February 1, 2000
    Date of Patent: October 8, 2002
    Assignee: Cytovia, Inc.
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, Yan Wang, Ben Tseng, Shailaja Kasibhatla, John A. Drewe